U.S. markets closed

Sophiris Bio, Inc. (SPHS)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0285-0.0025 (-8.06%)
At close: 2:27PM EDT
Sign in to post a message.
  • P
    Pumpkinpad
    Stock is still trading...patents still pending...no bankruptcy filing...no action from creditors...what am I missing here?
  • M
    Matt
    Look at the ownership and filings. What do you all think?
  • J
    Jean
    I added 30k more shares, still will add..
    Bullish
  • M
    Matt
    What’s this doing?
  • M
    Matt
    Anything at all?
  • r
    realtor0044
    i lost thousands on this stk last year. thought it was done. Hopefully, it can make a come back, got to take a chance.
    Bullish
  • S
    Sam
    Partnership rumored and needs shares accumulating. ..
    Bullish
  • T
    T
    does anyone know what's going on with Sophiris? 1.7m shares traded one day last week, up to .06 right now. Who's trying to get the band back together?
  • S
    Sam
    Hold on and add, something good will happening trust me on that...
    Bullish
  • T
    Tony
    We are not done yet we hopefully get some news dirt cheap buy buy buy ...
    Bullish
  • J
    John
    Pumpers abandoned ship.
    Bearish
  • S
    Sam
    I told you all to buy when it was 0.01 and still good time to buy,before ran to $1.00 a share...😀💰💰🚀
  • N
    Nelson
    http://dataunion.tistory.com/20089 Habitus seminate et metite characterem Courage_is_very_important._Like_a_muscle,_it_is_strengthened_by_use.
  • S
    Sam
    $SPHS Analysts rated as a Buy...😀💰💰🚀
    Bullish
  • S
    Sam
    Somebody knows something 😀💰💰🚀
  • D
    DigMoney
    I know this has been asked before but why is this still trading? I held on to my shares for s$%# and grins. Does anyone see anything happening with this stock in the future?
  • P
    Peter
    Very interesting........the chart is almost identical to ONCY which has the same kind of prospects (upcoming P3 study, potential BO) and ONCY has soared 1000% in the past month. Trust me, I'm still down big-time but I'm holding out for that possible partnership/BO. I also believe in the product (I'm a physician and think that there is a big market out there for a 30% prostate CA cure w/out the serious adverse fx of the alternative txs). Anyway, I guess we'll see soon either way.
  • c
    cathy
    The 2nd Quarter results today looked encouraging in the sense that there were no additional health issues with the patients who received the second dose. Financials look ok and the timeline for biopsy results was specified for late in Q4. So no surprises either way. Any thoughts?
  • T
    TRILLIUM
    - Increasing trade volume past five trading days and yesterday traded about 10x daily average.
    A blast up is SP might come unexpectedly.
    Be in it to prosper!
  • c
    cathy
    I think today's news is actually very good from a clinical point of view though things are dismal financially.
    The reason I think it is good news is as follows:
    The fact that a second dose had no effect demonstrates that only a single dose is required to cure prostate cancer IF the patients are properly screened. By this I mean that the 27% of the men who were cured (which in itself is astounding) with a single treatment clearly expressed the type of cancer that was amenable to Topsalysin. So once a clear determination of this class of prostate cancer has been made then this treatment will offer a high probability of a cure for these men.
    Of course, how long this cure lasts is another issue that can only be determined over time. Perhaps the cancer will never return or if it does return after a few years will it have mutated so it is not susceptible to Topsalysin again etc etc.
    The Phase III study needs to be designed around these types of cancers to demonstrate the efficacy of a single treatment to cure prostate cancer without any side effects.
    Then there were the partial responders. It was a binary event in that the second dose had no effect. This is great news too because the researchers can now determine the characteristics of those cancers which allowed a partial response one time. By so doing it may then be possible to modify Topsalysin for these cancers as well or perhaps combine it with an effector. This same approach can also be used to understand the third that had no response to their cancers, again suggesting how to modify the drug.
    All in a all this Phase 2b study was a textbook case of how to gather clinical data to design the Phase III trial which will lead to approval. The financing is another issue.